Asset Details
Do you wish to reserve the book?
Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors
Do you wish to request the book?
Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors
2025
Overview
Heat shock protein 90 (Hsp90) stabilizes numerous oncogenic proteins, making it a key therapeutic target in cancer. This protocol details an ex vivo method using freshly resected human renal cell carcinoma tissues to evaluate fluorescently labeled Hsp90 inhibitor ganetespib accumulation in tumor versus normal tissue. By preserving the native tumor architecture, this method offers a physiologically relevant alternative to xenograft models. This protocol combines flow cytometry and confocal microscopy to quantitatively and visually assess ganetespib uptake, providing insight into drug distribution and therapeutic response in human cancers. For complete details on the use and execution of this protocol, please refer to Dunn et al. and Woodford et al.
Publisher
Elsevier
Subject
